ArticleTranslational cancer research2025
SLC25A3 promotes hepatocellular carcinoma progression by inducing mitochondrial dysfunction and chromatin remodeling.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) represents one of the most life-threatening malignancies globally. Despite significant advancements in the treatment of HCC in recent years, therapeutic outcomes remain unsatisfactory, particularly for patients with advanced, inoperable HCC. Thus, there is an urgent need to identify novel therapeutic targets and develop combination therapies to enhance treatment efficacy. The aim of this study is to elucidate the role and mechanism of solute carrier family 25 member A3 (SLC25A3) in HCC. Methods: In this study, we examined the expression profiles and prognostic implications of mitochondrial-related gene sets in HCC using data from The Cancer Genome Atlas (TCGA) database. Among these genes, SLC25A3, a mitochondrial membrane protein, was found to be significantly overexpressed in HCC and associated with poor prognosis. To explore the potential role of SLC25A3 in HCC, we conducted analyses of clinical samples and performed in vivo and in vitro experiments. The underlying mechanisms were further investigated using multi-omics sequencing techniques. Results: The experimental results confirmed that SLC25A3 plays an oncogenic role in hepatocarcinogenesis, potentially by inducing mitochondrial dysfunction. Further multi-omics analysis revealed that the oncogenic effects of SLC25A3 in HCC may be mediated through its regulation of mitochondrial function and chromatin remodeling. Conclusions: These findings offer valuable insights for identifying potential therapeutic targets for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.